Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: Current evidence and future perspectives

Research output: Contribution to journalArticle

Abstract

The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.

Original languageEnglish
Pages (from-to)1207-1218
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume13
Issue number10
DOIs
Publication statusPublished - 2013

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
Platinum
Disease-Free Survival
Randomized Controlled Trials
Quality of Life
Drug Therapy

Keywords

  • afatinib
  • clinical trials
  • dacomitinib
  • EGFR
  • erlotinib
  • gefitinib
  • neratinib
  • NSCLC

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

@article{fb595fbb1ea64bfbae38b1dfc6cd5b19,
title = "Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: Current evidence and future perspectives",
abstract = "The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.",
keywords = "afatinib, clinical trials, dacomitinib, EGFR, erlotinib, gefitinib, neratinib, NSCLC",
author = "Raffaele Costanzo and Agnese Montanino and {Di Maio}, Massimo and Piccirillo, {Maria Carmela} and Claudia Sandomenico and Pasqualina Giordano and Gennaro Daniele and Renato Franco and Francesco Perrone and Gaetano Rocco and Nicola Normanno and Alessandro Morabito",
year = "2013",
doi = "10.1586/14737140.2013.845092",
language = "English",
volume = "13",
pages = "1207--1218",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations

T2 - Current evidence and future perspectives

AU - Costanzo, Raffaele

AU - Montanino, Agnese

AU - Di Maio, Massimo

AU - Piccirillo, Maria Carmela

AU - Sandomenico, Claudia

AU - Giordano, Pasqualina

AU - Daniele, Gennaro

AU - Franco, Renato

AU - Perrone, Francesco

AU - Rocco, Gaetano

AU - Normanno, Nicola

AU - Morabito, Alessandro

PY - 2013

Y1 - 2013

N2 - The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.

AB - The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.

KW - afatinib

KW - clinical trials

KW - dacomitinib

KW - EGFR

KW - erlotinib

KW - gefitinib

KW - neratinib

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84886390038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886390038&partnerID=8YFLogxK

U2 - 10.1586/14737140.2013.845092

DO - 10.1586/14737140.2013.845092

M3 - Article

C2 - 24134422

AN - SCOPUS:84886390038

VL - 13

SP - 1207

EP - 1218

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 10

ER -